

## **A multimorphic variant in ThPOK causes a novel human disease characterized by T cell abnormalities, immunodysregulation, allergy, and fibrosis**

Maryam Vaseghi-Shanjani<sup>1,2\*</sup>, Mehul Sharma<sup>2\*</sup>, Pariya Yousefi<sup>2</sup>, Simran Samra<sup>1,2</sup>, Kaitlin U. Lavery<sup>3</sup>, Arttu Jolma<sup>3</sup>, Rozita Razavi<sup>3</sup>, Ally H. W. Yang<sup>3</sup>, Mihai Albu<sup>3</sup>, Liam Golding<sup>2</sup>, Anna F. Lee<sup>4</sup>, Ryan Tan<sup>2</sup>, Phillip A. Richmond<sup>5</sup>, Marita Bosticardo<sup>6</sup>, Jonathan H. Rayment<sup>2</sup>, Connie L. Yang<sup>2</sup>, Kyla J. Hildebrand<sup>2</sup>, Rae Brager<sup>7</sup>, Michelle K. Demos<sup>2</sup>, Yu Lung Lau<sup>8</sup>, Luigi D. Notarangelo<sup>6</sup>, Timothy R. Hughes<sup>9</sup>, Catherine M. Biggs<sup>2†</sup>, Stuart E. Turvey<sup>2†</sup>

<sup>1</sup>Experimental Medicine Program, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.

<sup>2</sup>Department of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.

<sup>3</sup>Donnelly Centre, University of Toronto, Toronto, ON, Canada.

<sup>4</sup>Department of Pathology and Laboratory Medicine, BC Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.

<sup>5</sup>The Rare Disease Discovery Hub, BC Children's Hospital Research Institute, The University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada.

<sup>6</sup>Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.

<sup>7</sup>Division of Rheumatology, Immunology, and Allergy, Department of Paediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.

<sup>8</sup>Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.

<sup>9</sup>Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

\*Denotes equal contribution as co-first authors

†Denotes equal contribution as co-senior authors

### **Correspondence to:**

Stuart E. Turvey, MBBS, DPhil, FRCPC

BC Children's Hospital

950 West 28<sup>th</sup> Avenue

Vancouver, BC, V5Z 4H4, Canada

Email: [sturvey@bcchr.ca](mailto:sturvey@bcchr.ca)

## Abstract

ThPOK is best known as a regulator of CD4<sup>+</sup> T cell lineage commitment, although it was initially cloned as a suppressor of collagen expression in the skin. The role of ThPOK has not been formally established in humans since individuals with damaging variants in ThPOK have not yet been identified. Here, we report the first case of a human with a damaging heterozygous *de novo* variant in ThPOK causing a syndrome encompassing CD4<sup>+</sup> T cell deficiency, allergy, fibroinflammatory interstitial lung disease, developmental delay, and growth failure. The patient's variant, ThPOK<sup>K360N</sup>, exhibited abnormal multimorphic activity, including interfering with ThPOK<sup>WT</sup> in regulating gene regulation (antimorph). Protein-DNA interaction assays showed inability of ThPOK<sup>K360N</sup> to bind to wild-type consensus sequences (amorph) and revealed a novel DNA-binding specificity (neomorph). Single-cell RNA sequencing of peripheral blood revealed potential developmental defects in maturation and activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells (hypomorph). To establish causality, we recapitulated the observed cellular defects in lentivirally transduced healthy control T cells and pulmonary fibroblasts. Transcriptomic analysis showed that T cells transduced with ThPOK<sup>K360N</sup> lacked the upregulation of activation, proliferation, and functional pathways observed in ThPOK<sup>WT</sup>-transduced cells. When overexpressed in healthy control fibroblasts, ThPOK<sup>K360N</sup> significantly increased the expression of pro-fibrotic genes implicated in pulmonary fibrosis, indicating a defect in regulating collagen expression. This novel human disease caused by a multimorphic variant in ThPOK confirms its role in CD4<sup>+</sup> T cell development in an intact human context, while also revealing an unanticipated role for ThPOK in T cell function and the regulation of fibrotic pathways in fibroblasts.

**One sentence summary:** Discovery of a human with pathogenic multimorphic genetic change in ThPOK establishes ThPOK as essential for human T cell development and reveals its novel role as a regulator of fibrosis.

## 1 INTRODUCTION

2 T-helper-inducing POZ/Kruppel-like factor (ThPOK), encoded by *ZBTB7B*, is a transcription  
3 factor that belongs to the zinc finger and BTB/POZ domain-containing (ZBTB) family of proteins  
4 (1). ThPOK acts both as an activator and a suppressor of transcription through direct binding to  
5 promoter regions of target genes and by interaction with various co-regulators (2). In recent years,  
6 ThPOK has garnered significant attention in immunological research, primarily through insights  
7 gained from murine models. The most well-studied function of ThPOK is its role in directing the  
8 differentiation of T cell lineages, particularly in promoting the development of CD4<sup>+</sup> T cells and  
9 inhibiting the development of CD8<sup>+</sup> T cells in the thymus (3). This discovery was initially made  
10 based on a spontaneous mutant mouse strain with biallelic missense variants in the second zinc  
11 finger domain of ThPOK. These so-called ‘helper-deficient’ (HD) mice show a selective absence  
12 of mature CD4<sup>+</sup> T cells and increased frequency of CD8<sup>+</sup> T cells. While the primary focus on  
13 ThPOK has been its immune functions, its role extends to other biological processes, although  
14 these are less well-understood. For example, ThPOK is highly expressed in the skin and  
15 downregulates type I collagen gene expression in murine skin fibroblasts, binding specifically to  
16 the regulatory regions of type I collagen genes (*Colla1* and *Colla2*) (4).

17 Despite advances in our understanding of the role of ThPOK in immunity, the direct  
18 implications of *ZBTB7B* variants in human health have remained largely unexplored. To date,  
19 disabling genetic changes in ThPOK have not been implicated as a cause of human monogenic  
20 disease. Here, we describe a patient with a *de novo* heterozygous pathogenic variant in *ZBTB7B*  
21 causing a complex syndromic phenotype including CD4<sup>+</sup> T lymphopenia, CD8<sup>+</sup> T lymphocytosis,  
22 early-onset allergic disease, severe fibroinflammatory interstitial lung disease, and failure to thrive.  
23 Our detailed mechanistic investigations reveal that this variant is multimorphic, exhibiting

24 antimorphic dominant-negative (DN), amorphic and hypomorphic loss-of-function (LOF), and  
25 neomorphic gain-of-function (GOF) effects. Our findings, in the context of the whole human  
26 organism, both reinforce the well-established role of ThPOK in T cell development, as  
27 demonstrated by the patient's abnormalities in T cell development and function, but also emphasize  
28 the unexpected role of ThPOK in pulmonary fibrosis, as demonstrated by the increase in pro-  
29 fibrotic gene signature in fibroblasts expressing the variant. These findings not only elucidate and  
30 challenge the current understanding of ThPOK's role in the immune system, but also open new  
31 avenues for exploring its broader implications in other tissues and body systems in humans.

## 32 RESULTS

33

### 34 A novel *de novo* heterozygous *ZBTB7B* variant in a child with immunodeficiency, allergic 35 disease, and interstitial lung disease

36 The patient is young male child born to healthy non-consanguineous parents. His complex clinical  
37 course was notable for global developmental delay, failure to thrive (Figure S1), bilateral  
38 sensorineural hearing loss (Figure S2), non-healing corneal ulceration, increased echogenicity of  
39 multiple tissues (i.e. pancreas, liver and kidneys), growth hormone deficiency, allergic disease,  
40 combined immunodeficiency, and severe interstitial lung disease requiring supplemental oxygen  
41 (Figure 1A). He had persistent chest imaging abnormalities (Figure 1B-C) and lung biopsy  
42 demonstrated chronic inflammation and fibrosis of the lung, characterized by lipoproteinosis and  
43 notable subpleural cystic remodeling and honeycomb changes (Figure 1D-I).

44 Although T cell receptor excision circle (TREC) counts were normal at birth, CD4+  
45 lymphopenia was identified in infancy. Detailed immunophenotyping showed CD4+ lymphopenia  
46 and reduced naïve CD4+ T cell percentage, with the opposite finding in CD8+ T cells of  
47 lymphocytosis and elevated naïve percentage, and B cell lymphocytosis (Table S1).

48 Due to this unusual constellation of issues, trio whole-genome sequencing was pursued  
49 which identified a novel heterozygous *de novo* variant in *ZBTB7B* (NM\_001256455.2:c.1080A>C,  
50 p.K360N), predicted to be damaging using *in silico* prediction tools (Table S2). The sequencing  
51 results were validated by Sanger sequencing in all family members (Figure 1J-L). The variant  
52 results in a substitution from a positively charged lysine residue to a polar uncharged asparagine  
53 residue at a highly conserved region of the protein (Figure S3), altering the first zinc finger in the  
54 DNA-binding domain of ThPOK (Figure 1J).

55

56 **ThPOK<sup>K360N</sup> displays altered neomorphic DNA binding specificity**

57 We assessed the effect of the NM\_001256455.2:c.1080A>C (p.K360N) variant on protein  
58 expression using HEK293 cells. We selected HEK293 cells as our model system as these cells lack  
59 endogenous expression of ThPOK ([www.proteinatlas.org/](http://www.proteinatlas.org/)). Expression of ThPOK<sup>K360N</sup> was  
60 assessed both in isolation and in combination with ThPOK<sup>WT</sup>, modelling the patient's  
61 heterozygous state. Expression of ThPOK<sup>K360N</sup> remained comparable to ThPOK<sup>WT</sup> both in  
62 isolation and in the heterozygous state, suggesting that the presence of the variant does not impact  
63 protein expression (Figure 2A, Figure S4).

64 Next, we evaluated the effect of the variant on the function of ThPOK as a transcription  
65 factor and its regulatory influence on *SOCS1* expression. Building on Luckey *et al.*'s identification  
66 of ThPOK-binding sites within the mouse *Socs1* promoter region (5), we developed a luciferase  
67 reporter assay utilizing a segment of the human *SOCS1* promoter containing the previously  
68 identified DNA binding motif of ThPOK (6). We established that ThPOK<sup>K360N</sup> is impaired in its  
69 ability to upregulate *SOCS1* transcriptional activity compared to ThPOK<sup>WT</sup> (Figure 2B). When co-  
70 transfecting cells to mimic the heterozygous state with both wild-type (WT) and p.K360N *ZBTB7B*  
71 plasmids, the transcriptional activity of *SOCS1* exhibited an intermediate increase (Figure 2B). We  
72 then investigated the potential dominant-negative effect of ThPOK<sup>K360N</sup> on ThPOK<sup>WT</sup> by  
73 systematically increasing the ratio of the variant plasmid relative to the WT plasmid. Here we  
74 observed an inverse relationship between the amount of the variant plasmid and *SOCS1*  
75 transcriptional activity (Pearson correlation:  $r^2 = 0.9262$ , p-value = 0.0005) (Figure 2C).

76 To further assess the DNA-binding ability of ThPOK<sup>K360N</sup>, we employed an electrophoretic  
77 mobility shift assay (EMSA) using a tagged 35 nucleotide probe from the *SOCS1* promoter. We

78 observed that ThPOK<sup>WT</sup> could effectively bind to this probe, while ThPOK<sup>K360N</sup> could not (Figure  
79 S5). To ensure the observed binding was specific, a supershift assay was performed and confirmed  
80 that the ThPOK variant exhibited no detectable binding activity, indicating a loss of DNA-binding  
81 capability likely attributable to the missense change in the DNA-binding zinc finger (Figure 2D).  
82 Additionally, a competition assay with a 100-fold excess of unlabeled competitor probe  
83 substantially diminished the supershifted ThPOK<sup>WT</sup>-DNA complex band, further verifying the  
84 specificity of the binding (Figure 2E).

85 We used structural modeling to evaluate the predicted impact of the amino acid change at  
86 position 360 on the ability of ThPOK to interact with DNA, using the paralog ZBTB7A  
87 (PDB:8E3D), which shares sequence homology in the DNA-binding zinc finger domain with  
88 ThPOK (7). The structural analysis of ZBTB7A bound to a DNA target revealed that the lysine  
89 residue, equivalent to the changed 360 site in ThPOK, forms direct hydrogen bonds with the bases  
90 of AG dinucleotide. Consequently, the variant in ThPOK likely disrupts these interactions, altering  
91 its DNA binding specificity (Figure S6). To experimentally define and compare the DNA binding  
92 profiles of ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup>, we utilized high-throughput systematic evolution of  
93 ligands by exponential enrichment (HT-SELEX). The HT-SELEX results further corroborated  
94 changes in DNA binding specificity of ThPOK<sup>K360N</sup> compared to ThPOK<sup>WT</sup> (Figure 2F). Position  
95 weight matrices (PWM) revealed a shift in nucleotide preference in positions 3 and 4, specifically  
96 changing ‘GA’ nucleotides, preferred by the WT, to ‘CT’ or ‘AT’ nucleotides, preferred by  
97 ThPOK<sup>K360N</sup>. Notably, both ‘C’ and ‘A’ were similarly preferred at position 3 for ThPOK<sup>K360N</sup>  
98 (Figure 2F). Additionally, the relative abundance of 8-mer sequences from HT-SELEX  
99 experiments revealed that sequences with high affinity for either ThPOK<sup>WT</sup> or ThPOK<sup>K360N</sup>

100 generally had a low incidence in the counterpart's selection. This distinct separation underscores  
101 the divergent DNA binding specificities between ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup> (Figure 2G).

102         Given that the original 'GA' dinucleotide at positions 3 and 4 in the WT binding sequence  
103 is highly conserved and exhibits low flexibility, changes to this sequence are likely to impact  
104 binding specificity. To test this using EMSA, we created two variant oligonucleotide probes  
105 informed by the highest hit of the 8-mer plot (Variant Probe 1) and the consensus sequence for  
106 ThPOK<sup>K360N</sup> as indicated by PMW obtained from HT-SELEX (Variant Probe 2) that incorporated  
107 the dinucleotide modifications 'AT' (3'...CATCCCC...5') or 'CT' (3'...CCTCCACC...5')  
108 respectively (see Table S3 for full-length probe sequences). Our results demonstrated that  
109 ThPOK<sup>K360N</sup> exhibited strong binding affinity to Variant Probe 1 and 2 (Figure 2H).

110         To further assess the DNA binding landscape of the transcription factor, we integrated the  
111 HT-SELEX motifs with corresponding chromatin immunoprecipitation followed by sequencing  
112 (ChIP-seq) data to identify high-confidence gene targets for both ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup>. A  
113 gene was designated as a high-confidence target based on the co-occurrence of ChIP-seq peaks in  
114 all replicates within the promoter regions (spanning from -1000 to +500 bp relative to the  
115 transcription start site) that also harbored corresponding HT-SELEX motif hits (Figure 2I). Our  
116 analysis revealed distinct gene targets likely to be regulated by ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup>, as  
117 illustrated by the Venn diagram (Figure 2I), with limited overlap between the gene sets and  
118 associated pathways (data file S1) targeted by each protein, suggesting that ThPOK<sup>WT</sup> and  
119 ThPOK<sup>K360N</sup> engage in differential regulatory networks. This pattern indicates potentially unique  
120 transcriptional roles for each protein, which may underlie differences in cellular responses and  
121 phenotypic outcomes.

122



123 **Patient T cells have impaired development, memory phenotype skewing, and enhanced Th2**  
124 **effector function**

125 ThPOK plays a critical role in the development of lymphoid cells, particularly in the lineage  
126 commitment of CD4<sup>+</sup> T cells (1-3, 5, 8) (Figure 3A). To define how ThPOK<sup>K360N</sup> impacts T cell  
127 development, we first performed immunophenotyping of the patient's lymphoid compartment.  
128 Clinical flow cytometry data, collected over multiple time points, consistently revealed T cell  
129 abnormalities; notably persistent CD4<sup>+</sup> lymphopenia, CD8<sup>+</sup> lymphocytosis, and a lower  
130 CD4<sup>+</sup>/CD8<sup>+</sup> ratio, all while largely maintaining a normal absolute CD3<sup>+</sup> count in comparison to  
131 age-matched controls (Figure 3B). Clinical lymphocyte studies also indicated significant  
132 abnormalities in T cell naïve and memory subpopulations. The patient has persistently low  
133 proportion of CD4<sup>+</sup> naïve T cells and high proportion of CD4<sup>+</sup> central memory and effector  
134 memory T cells. Additionally, the CD8<sup>+</sup> T cell compartment shows an unusually high proportion  
135 of naïve T cells, while the percentages of CD8<sup>+</sup> central memory, effector memory, and TEMRA  
136 T cells are consistently low. This pattern underscores a persistent imbalance in the patient's T cell  
137 maturation and memory formation processes. Memory B cells also showed a skewed distribution,  
138 with low levels of switched, unswitched memory and transitional B cells and high levels of naïve  
139 B cells (Table S1).

140 Along with the clinical observation of severe atopic manifestations in the patient, we also  
141 observed transient peripheral blood eosinophilia in the first 2 years of life and persistently elevated  
142 serum IgE levels (Figure 3C). This prompted an examination of the T helper 2 (Th2) cell in patient  
143 primary cells. We conducted an immunophenotyping study using flow cytometry to analyze the T  
144 cell compartment using blood drawn from the patient at three different points over two years. For  
145 comparative analysis, we included three age-matched pediatric healthy controls (HC) and four

146 adult HCs. We first confirmed reduction in frequency of total CD4<sup>+</sup> T cells and increase in CD8<sup>+</sup>  
147 proportion in the CD3 compartment (Figure 3D). Within the CD4<sup>+</sup> T cell population, there was an  
148 increase in the frequency of memory T cells alongside a substantial decrease in naïve CD4<sup>+</sup> T cells  
149 in the patient, in line with the clinically collected data (Figure 3E). Upon stimulation with PMA  
150 and ionomycin, a marked increase in Th2 cell activity was observed in the patient. This was  
151 characterized by elevated production of Th2 effector cytokines, including IL-4, IL-5, and IL-13  
152 (Figure 3F-G). These findings suggest that the patient exhibits distinct immune dysregulation,  
153 particularly in the T cell compartment, with a pronounced shift towards memory phenotypes and  
154 Th2 effector function.

155

#### 156 **Patient T cells exhibit impaired differentiation and activation**

157 To understand the molecular underpinnings of the observed developmental T cell defect, we  
158 conducted single-cell RNA sequencing combined with antibody sequencing (scRNA-seq/Ab-seq)  
159 on the peripheral blood mononuclear cells (PBMCs) of the patient and two HCs, with and without  
160 T cell receptor (TCR) stimulation. Dimensionality reduction using UMAP on the unstimulated  
161 global transcriptomic signature did not place the patient's T cells, NK cells, B cells or monocytes  
162 in a separate cluster from those of the HCs (Figure 4A). Quantitative assessment of T cell subset  
163 proportions, as measured using surface marker sequencing, did confirm clinical flow cytometry  
164 data: the patient exhibited low CD4<sup>+</sup> T cells and high CD8<sup>+</sup> T cells (Figure 4B). However, T cells  
165 specific clustering, visualized with UMAP, revealed that the patient's T cells cluster separately  
166 from HC T cells. This difference in clustering was independent of CD4<sup>+</sup>, CD8<sup>+</sup> or naïve and  
167 memory (using CD45RO) subset classification as determined by cell surface staining (Figure 4C).  
168 Patient T cells were largely naïve CD8<sup>+</sup> but did not cluster with naïve T cells of HCs (Figure 4C).

169           Given the stark differences in transcriptomic signatures of patient T cells, we studied each  
170 of the key T cell subpopulations. Leveraging the BD® AbSeq Antibody-Oligonucleotides  
171 Conjugates, we were able to identify CD4<sup>+</sup> and CD8<sup>+</sup> expressing T cells in our scRNA-seq data.  
172 We examined double positive (DP) T cells, as they could reflect potential developmental defects  
173 in the final stages of T cell maturation in the thymus. We noted that the lineage commitment gene  
174 *TCF3* was upregulated in the patient's DP T cells compared to HCs (Figure 4D). The accumulation  
175 of *TCF3* could suggest a defect in the downstream mediators of CD4<sup>+</sup> T cell commitment, namely  
176 ThPOK and GATA3 (*9-11*). Subsequently, we investigated gene signatures in naïve CD4<sup>+</sup> and  
177 CD8<sup>+</sup> T cells. While we did not see differences between patient and HCs at baseline, we did see  
178 differences after TCR stimulation. Here, strong skewing was observed in both the naïve CD4<sup>+</sup> and  
179 CD8<sup>+</sup> compartment of patient T cells suggestive of impaired TCR activation compared to HCs  
180 (Figure 4E-H). A lack of T cell activation was particularly evident with patient cells failing to  
181 upregulate proliferative signaling pathways in CD4<sup>+</sup> T cells (e.g., the MYC pathway) and effector  
182 CD8<sup>+</sup> T cell pathways (e.g., interferon pathways) (Figure 4F and 4H). These results suggest a  
183 significant role for ThPOK in the activation of matured single-positive T cells. To establish this  
184 link experimentally, we stably transduced T cells with EV, WT, or p.K360N ThPOK containing  
185 lentiviral plasmids, and cultured them for 3 days. We observed that many pathways (e.g., MYC  
186 proliferation, and interferon effector) were upregulated in WT-transduced T cells, but these  
187 pathways failed to upregulate in p.K360N-transduced cells (Figure 3I). These results showed that  
188 the defects in T cell activation were attributable to the dominant-interfering effect of ThPOK<sup>K360N</sup>.  
189  
190 **ThPOK<sup>K360N</sup> disrupts profibrotic gene suppression in pulmonary fibroblasts**

191 In addition to the T cell defects, the patient carrying ThPOK<sup>K360N</sup> had evidence of multi-organ  
192 fibrosis, and it has previously been shown that murine ThPOK binds to the regulatory regions of  
193 collagen genes in the skin to inhibit their expression (4). Using HEK293 cells, which express  
194 *COL2A1* but lack endogenous expression of ThPOK, we compared the effects of transduced  
195 ThPOK<sup>K360N</sup> to ThPOK<sup>WT</sup>. Our results show that while ThPOK<sup>WT</sup> suppresses *COL2A1* expression  
196 as expected, ThPOK<sup>K360N</sup> does not, leading to significantly higher *COL2A1* levels similar to the  
197 control with an EV (Figure 5A). Additionally, cells expressing both ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup>,  
198 mimicking a heterozygous state, also showed significantly increased *COL2A1* expression  
199 compared to ThPOK<sup>WT</sup> alone (Figure 5A), indicating a dominant interfering effect of ThPOK<sup>K360N</sup>  
200 on ThPOK<sup>WT</sup> in repressing collagen expression. This led us to further validate our findings through  
201 stable lentiviral transduction, highlighting ThPOK's critical role in regulating collagen gene  
202 expression. Since ThPOK is highly expressed in fibroblasts ([www.proteinatlas.org/](http://www.proteinatlas.org/)) and acts as a  
203 repressor of murine *Colla1* and *Colla2* (also highly expressed in fibroblasts) (4), we utilized  
204 primary human pulmonary fibroblasts as a model system. HC pulmonary fibroblasts were stably  
205 transduced with either EV, WT, or p.K360N ThPOK containing lentiviral plasmids (Figure 5B).  
206 Principal component analysis (PCA) of bulk RNA sequencing data showed clear and distinct  
207 clustering for each group. Principal Component 1 (PC1) and PC2 accounted for 52.6% and 32.9%  
208 of the total variance, respectively, and highlighted large differences in gene expression profiles  
209 influenced by ThPOK status (Figure 5C). Differential analysis between EV-transduced and WT  
210 ThPOK-transduced fibroblasts showed significant gene expression changes, many of which are  
211 not observed to the same level in variant-transduced cells (Figure 5D). Interestingly,  
212 overexpression of ThPOK<sup>K360N</sup> led to altered gene expression profiles compared to ThPOK<sup>WT</sup>,  
213 with a number of genes that were upregulated in the WT being downregulated in the variant and

214 vice versa (Figure 5D and 5E). This shift indicates that the missense change in the first zinc finger  
215 of ThPOK significantly changes its regulatory impact, potentially altering its DNA-binding  
216 affinity, interaction with other proteins, or responsiveness to cellular signals.

217 Pathway analysis of the transcriptomic data revealed downregulation of critical pathways  
218 including interferon alpha and gamma signaling, as well as the inflammatory response pathway in  
219 the variant-transduced cells compared to WT-transduced controls. Conversely, upregulation was  
220 observed in several pathways, such as estrogen response late, Myc targets, and epithelial  
221 mesenchymal transition (Figure 5F). The upregulation of the epithelial mesenchymal transition, a  
222 pathway integral to fibrosis and wound healing, was notable as it underlined the variant's role in  
223 potentially exacerbating fibrotic conditions, highlighting a key area for further investigation. This  
224 is supported by the differential expression of several pro-fibrotic genes –*ACTA2* (12-20), *TGFBI*  
225 (18, 21, 22), *LTBP2* (19, 23, 24), and *BDNF* (25), and *COL1A1* (20, 26), and MDK (27)– that  
226 have been implicated in pulmonary fibrosis by multiple studies (Figure 5G). These genes have  
227 significantly increased transcript abundance in fibroblasts stably expressing ThPOK<sup>K360N</sup> to  
228 compared to WT controls. These findings suggest that ThPOK<sup>K360N</sup> represents a LOF in its ability  
229 to suppress fibrosis and profibrotic gene expression in fibroblasts, thereby highlighting the crucial  
230 role of ThPOK in maintaining cellular homeostasis against fibrotic processes.

231  
232 **Reversal of fibrotic gene signature in patient pulmonary fibroblasts is achieved by over-**  
233 **expression of WT ThPOK or pirfenidone treatment**

234 We next utilized patient-derived primary pulmonary fibroblasts to determine if stable  
235 overexpression of ThPOK<sup>WT</sup> could reverse the observed fibrotic gene signature (Figure 5H). Our  
236 results revealed that the previously identified profibrotic genes in the transduced HC pulmonary

237 fibroblasts exhibited similar differential regulation patterns in transduced patient-derived cells.  
238 Notably, there was a decrease in transcript abundance of the profibrotic genes in the patient-  
239 derived fibroblasts stably expressing the WT gene, thereby indicating a successful rescue of the  
240 patient-derived cells from the fibrotic phenotype (Figure 5I).

241 Building on our previous findings, we tested the efficacy of Food and Drug Administration  
242 (FDA)-approved pulmonary fibrosis drugs – pirfenidone (28-30) and nintedanib (29-31) – on  
243 patient-derived pulmonary fibroblasts in their steady state, and also under fibrosis-induced  
244 conditions. This approach was designed to better mimic the fibrotic microenvironment of the  
245 patient's lungs, acknowledging that *in vivo*, cells are influenced by surrounding signals and are not  
246 isolated. For the induction of a fibrotic cell model, we employed transforming growth factor beta  
247 (TGF- $\beta$ ) stimulation, a method well-established in the literature for simulating a fibrosis response  
248 in human fibroblasts (20, 30). We used *ACTA2* expression via qPCR as our primary readout, due  
249 its recognition in the literature as a critical marker of myofibroblasts and activated fibroblasts, key  
250 players in fibrotic disease progression across various organs, including the lungs (12-20). Optimal  
251 *in vitro* treatment doses were determined by conducting dose-response experiments and assessing  
252 cytotoxicity in our model system using the lactate dehydrogenate (LDH) release cytotoxicity assay  
253 (Figure S7). We demonstrated that treatment with pirfenidone (1mM) over a 48-hour period  
254 reduced *ACTA2* expression in TGF- $\beta$ -treated fibroblasts in comparison to untreated controls  
255 (Figure 5J). In contrast, a similar 48-hour treatment regimen with nintedanib (0.1 $\mu$ M) did not  
256 produce a comparable effect (Figure 5J). This finding highlights the efficacy of pirfenidone in  
257 modulating the fibrotic gene signature and may underscore the drugs' distinct mechanisms of  
258 action and their varied impact on fibrotic pathways in patient-derived pulmonary fibroblasts.

## 259 DISCUSSION

260 We describe the first reported human with a monogenic disorder caused by disruption of *ZBTB7B*  
261 which encodes the transcription factor ThPOK. This patient who was heterozygous for a variant  
262 in *ZBTB7B* presented with a complex syndromic phenotype including combined  
263 immunodeficiency, severe atopy, severe fibroinflammatory interstitial lung disease, sensorineural  
264 hearing loss, global developmental delay, and growth failure. Our investigations align with the  
265 established guidelines for genetic studies in single patients, as proposed by Jean-Laurent Casanova  
266 (32): the identified variant is not found in the unaffected parents or sibling; the variant is rare and  
267 absent in the gnomAD population database; *in silico* tools predict the variant to be damaging; and  
268 our functional investigations indicate that ThPOK<sup>K360N</sup> exhibits multimorphic damaging effects.

269 The discovery of a monogenic defect in ThPOK in our patient has offered an exciting  
270 opportunity to explore the role of ThPOK in human immunology, providing a direct *in vivo* context  
271 that was previously inaccessible and primarily inferred from the HD mice and *in vitro* human  
272 studies. ThPOK is best known for its role as a ‘master regulator’ of CD4<sup>+</sup> lineage commitment in  
273 the thymus, where it has been shown to be crucial for CD4<sup>+</sup> versus CD8<sup>+</sup> lineage decisions,  
274 particularly in MHC-II-restricted CD69<sup>+</sup> CD4<sup>+</sup> CD8<sup>low</sup> intermediate thymocytes (1-3, 8, 33-37).  
275 This was first discovered through the HD mouse model characterized by the selective absence of  
276 mature CD4<sup>+</sup> T cells in the periphery and increased numbers of CD8<sup>+</sup> cells (38). Our observations  
277 of persistent CD4<sup>+</sup> lymphopenia and CD8<sup>+</sup> lymphocytosis in the patient's T cell compartment  
278 recapitulate the phenotypic alterations seen in HD mice (5, 36, 37). HD mice are also noted to have  
279 markedly increased frequency of CD4<sup>+</sup> CD8<sup>low</sup> intermediate thymocytes (38). While this might  
280 suggest that class II-restricted thymocytes are arrested at this stage, ThPOK-deficient mice,  
281 including HD and knockout models, are reported to have MHC II-restricted CD8<sup>+</sup> cells in both

282 the thymus and spleen, suggesting that in the absence of functional ThPOK, MHC II-restricted  
283 thymocytes are reprogrammed to become CD8<sup>+</sup> cells. This is supported by *in vitro* studies that  
284 show ThPOK-deficient CD4<sup>+</sup> CD8<sup>low</sup> thymocytes can differentiate into CD8<sup>+</sup> cells (1, 34). This  
285 raises the question of whether all of the patient's CD8<sup>+</sup> cells are exclusively MHC I-restricted, or  
286 if the subset includes an MHC II-restricted component, an aspect that warrants further  
287 investigation.

288 Our study reveals significant differences in the clustering of T cells between the patient  
289 and HCs. While the patient's T cells were predominantly naïve CD8<sup>+</sup> cells, they did not align with  
290 the naïve CD8<sup>+</sup> T cell clusters of HCs. This observation implies that the patient's naïve CD8<sup>+</sup> T  
291 cells possess unique characteristics or alterations that distinguish them from their healthy  
292 counterparts. Several factors could contribute to this unique clustering. Differences in TCR  
293 repertoires or altered signaling pathways in comparison to HC counterparts could all play a role in  
294 the distinct T cell profile of the patient. The patient's immune environment might also influence T  
295 cell behavior and clustering. The altered clustering of naïve CD8<sup>+</sup> T cells might also reflect  
296 changes in their activation potential, survival, or differentiation capacity. Further investigation is  
297 required to elucidate the specific factors driving the distinct clustering of the patient's T cells.

298 In the context of CD4<sup>+</sup> T cell biology, our findings complement the established literature  
299 by demonstrating that ThPOK not only orchestrates the development of CD4<sup>+</sup> T cells in the  
300 thymus, but it also regulates the differentiation of several CD4<sup>+</sup> T helper cell subsets and the  
301 activation and memory potential of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the periphery (36, 39, 40).  
302 Notably, ThPOK plays a pivotal role in promoting Th2 cell differentiation while concurrently  
303 preventing the aberrant trans-differentiation of Th1/Th2 cells into cytotoxic T cell phenotypes (36,  
304 39). Our data present an unexpected finding regarding Th2 cells. Contrary to existing reports that



305 show the role of ThPOK in promoting Th2 cells (36, 39), the patient exhibited an increased Th2  
306 response, with a significant enhancement in effector cytokine production (IL-4, IL-5, and IL-13)  
307 upon PMA/Ionomycin stimulation, suggesting an unanticipated role of ThPOK in modulating Th2  
308 cell effector functions in humans. Our findings reveal an intriguing association between the  
309 observed increase in Th2 cell responsiveness and the patient's severe atopic manifestations, which  
310 encompass early-onset and severe allergic conditions. While our data indicate a distinct Th2 cell  
311 hyperresponsiveness mediated by the variant, it remains unclear whether the enhanced Th2  
312 responses are T cell intrinsic or influenced by other factors. It is possible that impaired regulatory  
313 T cell (Treg) differentiation or function, or altered basophil differentiation or function, may  
314 contribute to this phenotype. Additionally, assuming a T cell-intrinsic effect, the increased Th2  
315 responses could stem from a loss of normal ThPOK function or the gain of new functions by the  
316 variant protein in the allergic inflammatory pathway.

317 ThPOK is also recognized to be important for CD4<sup>+</sup> T cell activation, in particular  
318 preserving transcriptomic integrity and memory potential. In line with this, we observed a marked  
319 deficiency in the upregulation of genes essential for TCR-stimulated activation in naïve CD4<sup>+</sup> T  
320 cells from the patient compared to HCs, highlighting a significant deficit in proliferative signaling  
321 pathways, such as the MYC pathway. The introduction of ThPOK<sup>WT</sup> into T cells activated by TCR  
322 led to a notable upregulation of pathways critical for proliferation and effector functions, which  
323 were noticeably absent in cells transduced with the variant. Similarly, our research builds upon the  
324 known impact of ThPOK deficiency on clonal proliferation and effector molecule production in  
325 CD8<sup>+</sup> T cells. ThPOK deficiency is shown to markedly impair the clonal proliferation and the  
326 production of CD8<sup>+</sup> effector molecules, such as IL-2 and granzyme B, within long-lived CD8<sup>+</sup> T  
327 memory (T<sub>m</sub>) cells upon antigenic rechallenge (41). We identified a pronounced impairment in

328 the activation of naïve CD8<sup>+</sup> T cells in the patient, evidenced by a significant reduction in the  
329 upregulation of genes following TCR stimulation. This was particularly notable in the  
330 downregulation of effector pathways, such as those mediated by interferons, which are crucial for  
331 the functionality of CD8<sup>+</sup> T cells. These findings suggest a direct link between ThPOK function  
332 and the activation of mature single-positive T cells. Our results thus provide an understanding of  
333 ThPOK's role, not only in the differentiation and development of T cell subsets but also in their  
334 activation and functional response, thereby underscoring the complex regulatory mechanisms  
335 orchestrated by ThPOK in T cell immunobiology.

336 Beyond challenging the existing paradigm of ThPOK's role in immunity, our study  
337 significantly advances the understanding of ThPOK's function in human biology both  
338 mechanistically and clinically. Through transcriptomic analysis of transduced primary pulmonary  
339 fibroblasts, we uncovered substantial differences in pathway regulation between HC pulmonary  
340 fibroblasts expressing ThPOK<sup>WT</sup> and those expressing the variant. Notably, we observed an  
341 upregulation in the epithelial-mesenchymal transition pathway, which is particularly relevant due  
342 to its association with fibrotic conditions. In addition, overexpression of ThPOK<sup>K360N</sup> led to an  
343 exacerbated fibrotic gene signature, indicative of ThPOK's involvement in regulating fibrotic  
344 processes beyond its involvement in the immune system. This was further evidenced by  
345 experiments with patient-derived pulmonary fibroblasts, where overexpression of ThPOK<sup>WT</sup>  
346 reversed the fibrotic gene signature, pointing to ThPOK's therapeutic potential in mitigating  
347 fibrotic diseases. Thus, our study suggests that genetic changes within ThPOK could have  
348 substantial consequences on the gene expression landscape in pulmonary fibroblasts, offering new  
349 insights into lung cell biology. Moreover, our exploration of FDA-approved pulmonary fibrosis  
350 drugs on patient-derived fibroblasts revealed that pirfenidone significantly reduced the expression

351 of *ACTA2*, a marker of myofibroblasts and fibrosis, under both steady state and TGF- $\beta$ -induced  
352 fibrotic conditions. The demonstration of pirfenidone's ability to modulate the fibrotic gene  
353 signature in patient-derived fibroblasts is particularly promising as it suggests a possible  
354 therapeutic approach in managing the fibrotic aspects of diseases associated with ThPOK  
355 dysfunction. This finding not only emphasizes the value of targeted therapies in complex genetic  
356 diseases but also offers new insights into idiopathic pulmonary fibrosis and other fibrotic lung  
357 conditions. Additionally, echogenicity and functional abnormalities have been noted in the  
358 patient's liver and kidneys, although these have not been definitively characterized as fibrosis.  
359 Given this newly characterized involvement of ThPOK in fibroblast regulation, it prompts  
360 speculation about the potential presence of fibrosis in other organs related to this variant. However,  
361 the exploration of such a hypothesis is constrained by the ethical and clinical limitations on  
362 obtaining biopsies without a clear medical indication from the patient.

363 In conclusion, here we describe a novel human disease associated with a multimorphic  
364 damaging variant in ThPOK, establishing its causative link to the patient's clinical profile through  
365 complementary experimental approaches. This study not only broadens the scope of ThPOK's  
366 known functions in immune regulation but also reveals its tissue-dependent dual regulatory nature,  
367 impacting both immune cells and fibroblasts. While our findings offer significant insights, they  
368 are derived from a single patient, the only identified case to date, highlighting a limitation and the  
369 need for further discovery of similar cases to expand the disease phenotype. Our research opens  
370 avenues for further research which includes assessing the impact of ThPOK variants across  
371 different tissues and their potential role in non-immune pathologies and a longitudinal study to  
372 track the patient's disease progression. Moreover, further investigation into ThPOK's interactions  
373 within the immune system, particularly its role in the skewed Th2 immune response, is essential.

374 These future directions promise to deepen our understanding of ThPOK's multifaceted role in  
375 human health and disease, paving the way for improved clinical management and therapeutic  
376 strategies for patients with ThPOK variant-associated conditions.

## 377 MATERIALS AND METHODS

378

### 379 Study design

380 The patient with a previously uncharacterized disease was identified after presenting to the  
381 immunology clinic. Trio whole-genome sequencing identified a *de novo* heterozygous variant in  
382 *ZBTB7B* that results in a missense change in the DNA-binding domain of ThPOK. We uncovered  
383 the altered DNA binding specificity and transcriptional activity of the variant by multiple  
384 approaches, including electrophoretic mobility shift assay (EMSA), high-throughput systematic  
385 evolution of ligands by exponential enrichment (HT-SELEX), luciferase assay, and chromatin  
386 immunoprecipitation followed by sequencing (ChIP-seq). We performed extensive phenotyping  
387 of the patient's peripheral blood cells by single-cell RNA sequencing and conventional flow  
388 cytometry to reveal the abnormalities in T cell development, function and activation. To assess the  
389 mechanisms underlying the fibroinflammatory changes seen in the patient lung, we employed an  
390 *in vitro* system, utilizing lentiviral transduction to introduce both the wild-type (WT) and variant  
391 genes into primary pulmonary fibroblasts derived from healthy controls (HCs) and the patient. We  
392 also did treatment-testing using two Food and Drug Administration (FDA)-approved antifibrotic  
393 agents, one of which successfully reversed the fibrotic gene signature in patient primary pulmonary  
394 fibroblasts in an *in vitro* model of fibrosis.

395

### 396 Study approval

397 The study participant and his parents/guardians and sibling provided written informed consent.  
398 Research study protocols were approved by the University of British Columbia Clinical Research  
399 Ethics Board (H15-00641).

400

#### 401 **Genomic analysis**

402 Genomic DNA from the patient and parents were sequenced with paired-end reads on the Illumina  
403 platform by GeneDx. See supplementary methods for more details.

404

#### 405 **Histopathology**

406 A wedge biopsy was obtained from the edge of right upper lobe of the lung in a surgical open  
407 biopsy procedure. The immunohistochemistry stainings of the lung tissue were performed in BC  
408 Children's Hospital Pathology Laboratory with clinically validated antibodies and protocols.

409

#### 410 **Immunoblotting**

411 Protein detection was carried out using standard immunoblotting techniques. Details are further  
412 elaborated in the supplemental methods. Briefly, HEK293 cells were cultured, transfected with  
413 relevant plasmids, lysed, and proteins were extracted. The proteins were separated by SDS-PAGE,  
414 transferred to membranes, and probed with anti-ThPOK (D9V5T) Rabbit mAb (Cell Signalling  
415 Technology, 1:1000), anti-Myc-Tag (9B11) Mouse mAb (Sigma Aldrich, 1:1000), and anti- $\beta$ -  
416 Actin (8H10D10) Mouse mAb (Cell Signalling Technology, 1:20,000). Detection was performed  
417 using the Odyssey DLx Near-Infrared Fluorescence Imaging System.

418

#### 419 **Luciferase reporter assay**

420 A 1406 bp region of the promoter sequence of human *SOCS* (chr16:11,255,899-11,257,304 on  
421 GRCh38/hg38) was cloned into pGL4.20 [luc2/Puro] (Promega) firefly luciferase reporter  
422 plasmid. Detailed methods are provided in the supplemental section. Briefly, HEK293 cells were

423 seeded in 24-well plates and incubated for 24 hours before transfection with EV, WT, or p.K360N  
424 variant plasmids, either individually (250 ng each) or in combination to model heterozygosity with  
425 varying ratios of WT to p.K360N (total 250 ng). Each well also received 250 ng of *SOCS1*-  
426 luciferase reporter and 10 ng PGL4.74 renilla luciferase control plasmid. Transfections were  
427 performed using Lipofectamine™ 3000. After 24 hours, cell lysates were prepared, and luciferase  
428 activity was measured using the Dual-Glo Luciferase Assay Kit (Promega) and a plate reader. In  
429 the analysis, firefly luciferase activity was normalized to renilla luciferase to account for  
430 transfection efficiency. This normalized activity was then divided by the value from the EV  
431 condition, providing a relative measure against the EV baseline.

432

### 433 **Electrophoretic mobility shift assay (EMSA)**

434 Preparation of whole cell lysates was performed as previously described in the immunoblotting  
435 section above. A section of the *SOCS1* promoter, containing the WT ThPOK consensus DNA-  
436 binding sequence along with two variant sequences identified by HT-SELEX as preferentially  
437 bound by variant ThPOK, were used to design the double stranded oligonucleotide probes used in  
438 this assay (see Table S3 for sequences). Supershift assays were performed with 5 µg of whole cell  
439 protein lysate incubated on ice for 30 min with either anti-ThPOK (D9V5T) Rabbit mAb (Cell  
440 Signalling Technology, 1:1000) or Rabbit IgG Isotype Control (Invitrogen, Thermo Fisher  
441 Scientific) and then incubated at room temperature for 20 min with the labelled DNA probes and  
442 reagents provided in the Odyssey® EMSA Kit (LI-COR Biosciences) according to the  
443 manufacturer's recommendations. Protein-oligonucleotide-antibody mixtures were then subjected  
444 to electrophoresis in 5% acrylamide/Bis-acrylamide 29:1 gel in 1x Tris-borate-EDTA (TBE)

445 migration buffer (Thermo Scientific) for 90 min at 70 V at room temperature. Imaging was done  
446 using the Odyssey DLx Near-Infrared Fluorescence Imaging System (LI-COR Biosciences).

447

#### 448 **High Throughput Systematic Evolution of Ligands by EXponential Enrichment (HT-** 449 **SELEX)**

450 WT and variant ThPOK (ZBTB7B\_WT and ZBTB7B\_K360N) were cloned into an eGFP  
451 expression vector pF3A-ResEnz-egfp. The TF samples were expressed by using a TNT SP6 High-  
452 Yield Wheat Germ Protein Expression System Kit (Promega). HT-SELEX was modified from our  
453 previous approach (6) to use Abcam Anti-GFP antibody ab290 immobilized to Protein G Mag  
454 Sepharose® Xtra Cytiva 28-9670-70) in the step where the protein–DNA complexes are separated  
455 from unbound DNA. The assay similarly used IVT-produced proteins, and the selection reactions  
456 were carried out in a buffer of 140 mM KCl, 5 mM NaCl, 1 mM K<sub>2</sub>HPO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 100 μM  
457 EGTA, 1 mM ZnSO<sub>4</sub>, and 20 mM HEPES-HCl (pH 7). After each of the three selection cycles,  
458 the ligands were amplified by PCR and output from all cycles was subjected to Illumina  
459 sequencing. Mung Bean Nuclease treatment also was used between each of the selection cycles to  
460 reduce the ssDNA background during the ligand selection. Data analysis was performed as  
461 previously described (42), where automatic detection of a sequence pattern defining local maxima  
462 was followed by semi manual generation of seeds that were then used to construct multinomial-1  
463 or multinomial-2 position frequency matrices for the transcription factor target specificity.

464

#### 465 **Chromatin Immunoprecipitation Sequencing (ChIP-seq)**

466 To establish GFP-tagged ThPOK expressing HEK293 Flp-In-TREx cell lines, parental HEK293  
467 Flp-In-TREx cells were transfected with separate expression vectors each carrying the WT or



468 variant *ZBTB7B* open reading frames (FuGENE® HD Transfection Reagent, Promega) and after  
469 48 hours transferred to Hygromycin selection media (0.2 ug/ul). Colonies of each line were pooled  
470 and used for further experiments. 24 hours prior to cross linking for chromatin  
471 immunoprecipitation, doxycycline (100 ng/ml) was added to cells and GFP expression was  
472 confirmed with fluorescent microscopy. Chromatin immunoprecipitation was performed as  
473 previously described (43). In brief, cells from 15 cm plates at 100% confluency were cross-linked  
474 for 10 min in 1% formaldehyde followed by 10 min of quenching with 2M glycine. After washing  
475 the cells with cold PBS, cells were collected and pelleted. Using a three-step lysis process,  
476 chromatin was released and then sonicated to produce DNA fragment length range of 200–300 bp  
477 using a Bioruptor sonicator (Diagenode). GFP-tagged proteins were immunoprecipitated with a  
478 polyclonal anti-GFP antibody (ab290, Abcam) and Dynabeads Protein G (Invitrogen). Crosslinks  
479 were reversed at 65°C overnight and bound DNA fragments were purified (QIAquick PCR  
480 Purification Kit, Qiagen). ChIP libraries were prepared using NEBNext Ultra II DNA kit.  
481 Sequencing was performed with 150n paired end at  $2 \times 10^7$  reads per sample. For each variant of  
482 *ZBTB7B*, two biological replicates and two input control samples were sequenced using NovaSeq  
483 6000 Illumina sequencer.

484 In the data processing step, adapter sequences were trimmed from ChIP-seq reads with  
485 Cutadapt (v2.1) (<https://doi.org/10.14806/ej.17.1.200>) and mapped to the human genome (hg38)  
486 with Bowtie2 (v2.4.1) (44) using the `-very-sensitive` option. Reads with a map quality of less than  
487 30 were discarded along with PCR duplicates and reads for which one or both of the paired ends  
488 could not be mapped. A single set of control reads was generated using the four-input control  
489 ChIP-seq replicates by merging them with SAMTools (v1.9) (45) and subsampling to one quarter  
490 of the total reads. MACS2 (v2.2.9.1) (46) was used to call peaks for each of WT and variant

491 ThPOK ChIP-seq replicates using the merged input read set as the control. For each set of peaks,  
492 the top 2000 peaks with the highest enrichment scores were used for downstream analyses.

493 For each WT ThPOK ChIP replicate, we scanned the peak sequences to identify peaks that  
494 contained a match to the HT-SELEX WT ThPOK motif using FIMO (v5.5.0) (47) with default  
495 settings. Using BEDTools intersect (v2.30.0) (48), we overlapped the motif-containing ChIP peak  
496 summits for each replicate with a BED file containing the locations of human gene promoter  
497 regions (1000 bp upstream of the transcription start site to 500 bp downstream). To establish a set  
498 of high-confidence candidates for direct regulation by WT ThPOK, we took the intersection of  
499 genes identified from each replicate. We then performed the same analysis using the variant  
500 ThPOK ChIP replicates and the variant ThPOK HT-SELEX motif. We searched for  
501 overrepresented pathways in the set of high-confidence ThPOK regulated genes and variant  
502 ThPOK regulated genes using the PANTHER statistical overrepresentation test with PANTHER  
503 pathways (49). We checked each set in its entirety, each set excluding genes that overlapped with  
504 the other set, and the intersection of the two sets. We report all overrepresented PANTHER  
505 pathways with a false discovery rate  $P < 0.05$ .

506

### 507 **Isolation and culture of primary pulmonary fibroblasts**

508 Fresh lung tissue was collected from the patient undergoing open lung biopsy for histopathological  
509 evaluation of interstitial lung disease. The tissue was immediately transported to the laboratory in  
510 ice-cold Dulbecco's Modified Eagle Medium (Thermo Fisher Scientific) supplemented with 1%  
511 penicillin-streptomycin (Thermo Fisher Scientific). We followed an optimized published method  
512 for generating a fibroblast-enriched single-cell suspension combining mechanical and enzymatic

513 dissociation. Concentrations for all the reagents used are reported in the original study (50). The  
514 processed cells were grown using Fibroblast Growth Medium 2 (PromoCell).

515

### 516 **Lentiviral transduction of primary pulmonary fibroblasts**

517 To generate lentivirus vectors, WT, and p.K360N cDNA from the previously described expression  
518 plasmids were cloned into a GFP-tagged Lenti vector (cat #PS100071, OriGene) using EcoRI-HF  
519 and NotI-HF (New England BioLabs). The sequence-verified lentiviral plasmids were packaged  
520 using 3rd generation packaging plasmids and transfected into HEK293T cells using  
521 Lipofectamine™ 3000 Transfection Reagent (Thermo Fisher Scientific). Viral supernatant was  
522 harvested and filtered through a 0.45 µm PES filter (Thermo Scientific Nalgene) and concentrated  
523 using an Amicon Ultra-15 100 kDa centrifugal filter (Millipore). The concentrated lentivirus  
524 solution was then aliquoted and stored at -80°C until use. To establish patient-derived and healthy  
525 control-derived pulmonary fibroblasts that stably express WT and p.K360N, patient and healthy  
526 control cells were infected with EV, WT, or p.K360N lentiviral particles and 5µg/ml polybrene  
527 (Sigma-Aldrich) through spinfection at 1000 x g for 2 hours at 32°C, cultured, and expanded in  
528 Fibroblast Growth Medium 2 (PromoCell) for 3 days before undergoing sorting based on GFP  
529 expression using BD FACS Aria (BD Biosciences) cell sorter.

530

### 531 **RNA sequencing**

532 To investigate the global transcriptome of the transduced patient and HC primary pulmonary  
533 fibroblasts stably expressing EV, WT, or p.K360N variant, 150,000 GFP+ cells were sorted based  
534 on GFP expression using BD FACS Aria (BD Biosciences) cell sorter directly into 500 ul of cold  
535 Buffer RLT Plus (Qiagen) supplemented with 2-Mercaptoethanol according to the Qiagen RNeasy

536 Plus Mini Kit instructions. Following sorting, the volume of Buffer RLT Plus was adjusted so that  
537 there was exactly 350 ul of Buffer RLT Plus to 100 ul of sorted sample volume. RNA isolation  
538 was done according to the RNeasy Plus Mini Kit instructions (Qiagen). Sequencing was done on  
539 rRNA depleted RNA libraries using PE150 Illumina NovaSeq Sequencing, targeting 100M  
540 individual reads (50M read pairs/clusters) per sample. Three biological replicates were included  
541 for each condition, which were independently transduced, sorted, and sequenced.

542 Sequenced reads were aligned to a reference sequence using Spliced Transcripts Alignment  
543 to a Reference aligner. E1 Assembly and expression were estimated using Cufflinks E2 through  
544 bioinformatics apps on Illumina BaseSpace. Expression data was normalized to reads between  
545 samples using the edgeR package in R (R Foundation). Normalized counts were filtered to remove  
546 low counts using the filterByExpr function in edge. Principal component analysis (PCA) was done  
547 on log<sub>2</sub> (normalized counts+0.25) in R using the PCA function. Differential expression analysis  
548 was accomplished using Limma. Differentially expressed genes were defined as those with  
549 adjusted p-value less than 0.05.

550 Pathway analysis was done by first performing Gene set enrichment analysis (GSEA) with  
551 1000 permutations using the Molecular Signatures Database Hallmark module. Signal-to-noise  
552 ratio was used for gene ranking and the obtained P-values were further adjusted using the  
553 Benjamini-Hochberg method. Pathways with an adjusted P-value <0.05 were considered  
554 significant. Leading edge genes from significant pathways between WT and p.K360N-transduced  
555 cells were identified. Expression levels of these genes were then determined in each group.

556 Sample level enrichment analyses (SLEA) scores were computed for each significant  
557 pathway. Briefly, z-scores were computed for gene sets of interest for each sample. The mean  
558 expression levels of significant genes were compared to the expression of 1000 random gene sets

559 of the same size. The difference between observed and expected mean expression was then  
560 calculated and represented on heatmaps generated using Morpheus  
561 (<https://software.broadinstitute.org/morpheus>).

562

### 563 **Single cell-RNA sequencing (scRNA-seq)**

564 Using single cell RNA-Sequencing (scRNA-seq), whole transcriptome analysis (WTA) was  
565 conducted on peripheral blood mononuclear cells (PBMCs) from the patient and three age-  
566 matched healthy controls. The BD Rhapsody Single Cell platform was used, which included the  
567 Rhapsody Enhanced Cartridge Reagent Kit (BD), the BD Rhapsody Cartridge Kit (BD), the  
568 Rhapsody cDNA Kit (BD), the Rhapsody WTA Amplification Kit (BD), the Human Single-Cell  
569 Multiplexing Kit (BD), used according to manufacturer's recommendations and protocols. Briefly,  
570 thawed PBMCs were rested overnight and then stimulated with ImmunoCult™ Human CD3/CD28  
571 T Cell Activator (STEMCELL Technologies) or left untreated for 16 hours. Cells from each donor  
572 were then labelled with sample tags and a panel of BD® AbSeq Ab-oligos (BD), washed with  
573 stain buffer, and pooled together in cold sample buffer to obtain ~60,000 cells in 620 ul for each  
574 of the pooled unstimulated and stimulated samples. Two nanowell cartridges were primed and  
575 subsequently loaded with the pooled samples. Libraries for whole transcriptome and AbSeq  
576 analysis were prepared by following the BD Rhapsody System (TCR/BCR Full Length, mRNA  
577 WTA, BD® AbSeq, and Sample Tag Library Preparation) Protocol. Quality control was  
578 performed using Agilent DNA High Sensitivity Kit (Agilent Technologies) and the Agilent 2100  
579 Bioanalyzer (Agilent Technologies) on the intermediate and final sequencing libraries, including  
580 estimating the concentration of each sample, measuring the average fragment size of the libraries,  
581 and following sequencing recommendations. Libraries were diluted to 350-650 picomolar range

582 per sample and sequenced using Illumina NovaSeq 150bp PE sequencing targeting 8,000M  
583 individual reads (4,000M read-pairs) with PhiX spike-in of 20%.

584 FASTQ files were processed using the BD Rhapsody Targeted Analysis Pipeline and Seven  
585 Bridges ([www.sevenbridges.com](http://www.sevenbridges.com)) according to manufacturer's recommendations. The R package  
586 Seurat was utilized for all downstream analysis. Scaling and clustering were performed on each  
587 pool of samples independently. Dimensionality reduction using PCA was done on the most  
588 variable genes, and UMAP was based on the first 20 PCs. Cell identities were annotated manually,  
589 or via cell surface antibody sequencing (Ab-seq), to first identify major cell types (T cells, B cells,  
590 NK cells and Monocytes) and then defining subtypes (CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, Double  
591 Positive T cells, and their subsequent Naïve and Memory subgroups). For differential gene  
592 expression analyses, we utilized the Seurat implementation of negative binomial test, assuming an  
593 underlying negative binomial distribution in RNA-Seq data while leveraging the UMI counts to  
594 remove technical noise.

595

## 596 **Flow cytometry**

597 To carry out immunophenotyping and intracellular cytokine detection, PBMCs from the patient  
598 and age-matched healthy controls were stimulated with eBioscience™ Cell Stimulation Cocktail  
599 (Invitrogen, Thermo Fisher Scientific) for 5 hours at 37°C. One hour after the start of stimulation,  
600 eBioscience™ Protein Transport Inhibitor Cocktail (Invitrogen, Thermo Fisher Scientific) was  
601 added to the stimulated cells. Cells were then stained with a cocktail of antibodies against surface  
602 markers for 20 minutes in room temperature and then fixed with Foxp3 Fixation/Permeabilization  
603 working solution from the eBioscience Foxp3 Transcription Factor Staining Buffer Set  
604 (Invitrogen, Thermo Fisher Scientific) for 20 minutes. The fixed cells were subsequently stained

605 for 20 minutes with antibodies targeting intracellular cytokines in 1x Permeabilization Buffer  
606 (Invitrogen, Thermo Fisher Scientific). The samples were then washed and analyzed using the BD  
607 FACSymphony flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (BD  
608 Biosciences). The antibody panels used for staining are listed in Table S4.

609

### 610 **Treatment testing and qPCR of primary fibroblasts**

611 Primary patient pulmonary fibroblasts were used to evaluate the effects of various treatments.  
612 Initially,  $5 \times 10^5$  cells were plated in each well of a 6-well plate (Corning) containing Fibroblast  
613 Growth Medium 2 (PromoCell). The cells were incubated overnight under standard conditions.  
614 Subsequently, they were either left untreated or treated with recombinant human TGF- $\beta$ 1 (R & D  
615 Systems) at a concentration of 5 ng/ $\mu$ l for 24 hours to induce a fibrotic state, a well-established *in*  
616 *vitro* model of fibrosis as documented in existing literature. Following the TGF- $\beta$ 1 treatment, cells  
617 were subjected to treatment with Nintedanib (working concentration of 0.1  $\mu$ M) or Pirfenidone  
618 (working concentration of 1 mM) for an additional 48 hours. Both drugs were purchased from  
619 MedChemExpress. For the groups designated to continue with TGF- $\beta$ 1 exposure, fresh medium  
620 supplemented with TGF- $\beta$ 1 was added concurrently with the drug treatments. This experimental  
621 setup allowed for the assessment of drug efficacy in both the presence and absence of an induced  
622 fibrotic environment. Post treatment, total RNA was extracted using a RNeasy Plus Mini Kit  
623 (Qiagen) and converted to cDNA using an iScript cDNA synthesis kit (BioRad Laboratories).  
624 Transcript abundance was measured using a Universal SYBR Green Super Mix (Bio-Rad) and a  
625 7300 Real-Time PCR System (Applied Biosystems). Relative transcript abundance was quantified  
626 relative to Actin- $\beta$  (*ACTB*) using the  $2^{-\Delta\Delta CT}$  method. Pre-designed qPCR primers were purchased  
627 from Integrated DNA Technologies.

628

629 **Statistical Analysis**

630 All data are presented as mean  $\pm$  standard error of the mean (SEM). Statistical significance was  
631 evaluated using appropriate methods for each dataset which are detailed in the corresponding  
632 figure legends or the methods section, with the following annotations used to represent  
633 significance: p-val < 0.05 (\*), p-val < 0.01 (\*\*), p-val < 0.001 (\*\*\*)).

634

635 **Supplementary Materials**

636 Materials and Methods

637 Figures S1 to S7

638 Tables S1 to S4

639 Data file S1



640 **References**

- 641
- 642
- 643 1. D. J. Kappes, Expanding roles for ThPOK in thymic development. *Immunol. Rev.* **238**,
- 644 182-194 (2010).
- 645 2. Z.-Y. Cheng, T.-T. He, X.-M. Gao, Y. Zhao, J. Wang, ZBTB Transcription Factors: Key
- 646 Regulators of the Development, Differentiation and Effector Function of T Cells. *Front.*
- 647 *Immunol.* **12**, (2021).
- 648 3. X. He, K. Park, D. J. Kappes, The Role of ThPOK in Control of CD4/CD8 Lineage
- 649 Commitment. *Annu. Rev. Immunol.* **28**, 295-320 (2010).
- 650 4. P. Galéra, R.-W. Park, P. Ducy, M.-G. Mattéi, G. Karsenty, c-Krox Binds to Several Sites
- 651 in the Promoter of Both Mouse Type I Collagen Genes. *J. Biol. Chem.* **271**, 21331-21339
- 652 (1996).
- 653 5. M. A. Luckey, M. Y. Kimura, A. T. Waickman, L. Feigenbaum, A. Singer, J.-H. Park, The
- 654 transcription factor ThPOK suppresses Runx3 and imposes CD4+ lineage fate by inducing
- 655 the SOCS suppressors of cytokine signaling. *Nat. Immunol.* **15**, 638-645 (2014).
- 656 6. A. Jolma, J. Yan, T. Whittington, J. Toivonen, Kazuhiro, P. Rastas, E. Morgunova, M.
- 657 Enge, M. Taipale, G. Wei, K. Palin, Juan, R. Vincentelli, Nicholas, Timothy, P. Lemaire,
- 658 E. Ukkonen, T. Kivioja, J. Taipale, DNA-Binding Specificities of Human Transcription
- 659 Factors. *Cell* **152**, 327-339 (2013).
- 660 7. R. Ren, J. R. Horton, Q. Chen, J. Yang, B. Liu, Y. Huang, R. M. Blumenthal, X. Zhang,
- 661 X. Cheng, Structural basis for transcription factor ZBTB7A recognition of DNA and
- 662 effects of ZBTB7A somatic mutations that occur in human acute myeloid leukemia. *J. Biol.*
- 663 *Chem.* **299**, 102885 (2023).
- 664 8. A. C. Carpenter, J. R. Grainger, Y. Xiong, Y. Kanno, H. H. Chu, L. Wang, S. Naik, L. dos
- 665 Santos, L. Wei, M. K. Jenkins, J. J. O'Shea, Y. Belkaid, R. Bosselut, The Transcription
- 666 Factors Thpok and LRF Are Necessary and Partly Redundant for T Helper Cell
- 667 Differentiation. *Immunity* **37**, 622-633 (2012).
- 668 9. L. B. Chopp, V. Gopalan, T. Ciucci, A. Ruchinskas, Z. Rae, M. Lagarde, Y. Gao, C. Li,
- 669 M. Bosticardo, F. Pala, F. Livak, M. C. Kelly, S. Hannenhalli, R. Bosselut, An Integrated
- 670 Epigenomic and Transcriptomic Map of Mouse and Human alphabeta T Cell Development.
- 671 *Immunity* **53**, 1182-1201 e1188 (2020).
- 672 10. W. Xu, T. Carr, K. Ramirez, S. McGregor, M. Sigvardsson, B. L. Kee, E2A transcription
- 673 factors limit expression of Gata3 to facilitate T lymphocyte lineage commitment. *Blood*
- 674 **121**, 1534-1542 (2013).
- 675 11. T. Egawa, Runx and ThPOK: A balancing act to regulate thymocyte lineage commitment.
- 676 *J. Cell. Biochem.* **107**, 1037-1045 (2009).
- 677 12. B. Hu, Z. Wu, T. Nakashima, S. H. Phan, Mesenchymal-Specific Deletion of C/EBP $\beta$
- 678 Suppresses Pulmonary Fibrosis. *Am. J. Pathol.* **180**, 2257-2267 (2012).
- 679 13. X. Liu, S. C. Rowan, J. Liang, C. Yao, G. Huang, N. Deng, T. Xie, D. Wu, Y. Wang, A.
- 680 Burman, T. Parimon, Z. Borok, P. Chen, W. C. Parks, C. M. Hogaboam, S. S. Weigt, J.
- 681 Belperio, B. R. Stripp, P. W. Noble, D. Jiang, Categorization of lung mesenchymal cells in
- 682 development and fibrosis. *iScience* **24**, 102551 (2021).
- 683 14. J. Sun, Y. Guo, T. Chen, T. Jin, L. Ma, L. Ai, J. Guo, Z. Niu, R. Yang, Q. Wang, X. Yu,
- 684 H. Gao, Y. Zhang, W. Su, X. Song, W. Ji, Q. Zhang, M. Huang, X. Fan, Z. Du, H. Liang,

- 685 Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF. *Cell. Death.*  
686 *Dis.* **13**, (2022).
- 687 15. J. R. Rock, C. E. Barkauskas, M. J. Cronce, Y. Xue, J. R. Harris, J. Liang, P. W. Noble, B.  
688 L. M. Hogan, Multiple stromal populations contribute to pulmonary fibrosis without  
689 evidence for epithelial to mesenchymal transition. *Proc. Natl. Acad. Sci. U.S.A* **108**, E1475-  
690 E1483 (2011).
- 691 16. H. N. Alsafadi, C. A. Staab-Weijnitz, M. Lehmann, M. Lindner, B. Peschel, M.  
692 Königshoff, D. E. Wagner, An ex vivo model to induce early fibrosis-like changes in  
693 human precision-cut lung slices. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **312**, L896-L902  
694 (2017).
- 695 17. F. Nosrati, J. Grillari, M. Azarnia, M. Nabiuni, R. Moghadasali, L. Karimzadeh, I.  
696 Lämmermann, The expression of fibrosis-related genes is elevated in doxorubicin-induced  
697 senescent human dermal fibroblasts, but their secretome does not trigger a paracrine  
698 fibrotic response in non-senescent cells. *Biogerontology* **24**, 293-301 (2023).
- 699 18. T. Wynn, Cellular and molecular mechanisms of fibrosis. *J. Pathol.* **214**, 199-210 (2008).
- 700 19. R. Peyser, S. MacDonnell, Y. Gao, L. Cheng, Y. Kim, T. Kaplan, Q. Ruan, Y. Wei, M. Ni,  
701 C. Adler, W. Zhang, K. Devalaraja-Narashimha, J. Grindley, G. Halasz, L. Morton,  
702 Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell  
703 Sequencing. *Am. J. Respir. Cell Mol. Biol.* **61**, 74-85 (2019).
- 704 20. M. Chioccioli, S. Roy, R. Newell, L. Pestano, B. Dickinson, K. Rigby, J. Herazo-Maya, G.  
705 Jenkins, S. Ian, G. Saini, S. R. Johnson, R. Braybrooke, G. Yu, M. Sauler, F. Ahangari, S.  
706 Ding, J. Deiuliis, N. Aurelien, R. L. Montgomery, N. Kaminski, A lung targeted miR-29  
707 mimic as a therapy for pulmonary fibrosis. *eBioMedicine* **85**, 104304 (2022).
- 708 21. J. C. Bonner, Mesenchymal cell survival in airway and interstitial pulmonary fibrosis.  
709 *Fibrogenesis Tissue Repair.* **3**, 15 (2010).
- 710 22. Y. Enomoto, H. Katsura, T. Fujimura, A. Ogata, S. Baba, A. Yamaoka, M. Kihara, T. Abe,  
711 O. Nishimura, M. Kadota, D. Hazama, Y. Tanaka, Y. Maniwa, T. Nagano, M. Morimoto,  
712 Autocrine TGF-beta-positive feedback in profibrotic AT2-lineage cells plays a crucial role  
713 in non-inflammatory lung fibrogenesis. *Nat. Commun.* **14**, 4956 (2023).
- 714 23. M. Zou, J. Zou, X. Hu, W. Zheng, M. Zhang, Z. Cheng, Latent Transforming Growth  
715 Factor- $\beta$  Binding Protein-2 Regulates Lung Fibroblast-to-Myofibroblast Differentiation in  
716 Pulmonary Fibrosis via NF- $\kappa$ B Signaling. *Front. Pharmacol.* **12**, (2021).
- 717 24. Y. Enomoto, S. Matsushima, K. Shibata, Y. Aoshima, H. Yagi, S. Meguro, H. Kawasaki,  
718 I. Kosugi, T. Fujisawa, N. Enomoto, N. Inui, Y. Nakamura, T. Suda, T. Iwashita, LTBP2  
719 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary  
720 fibrosis. *Clin. Sci.* **132**, 1565-1580 (2018).
- 721 25. E. Cherubini, S. Mariotta, D. Scozzi, R. Mancini, G. Osman, M. D'Ascanio, P. Bruno, G.  
722 Cardillo, A. Ricci, BDNF/TrkB axis activation promotes epithelial-mesenchymal  
723 transition in idiopathic pulmonary fibrosis. *J. Transl. Med.* **15**, (2017).
- 724 26. M. Jia, L. Rosas, M. G. Kapetanaki, T. Tabib, J. Sebrat, T. Cruz, A. Bondonese, A. L.  
725 Mora, R. Lafyatis, M. Rojas, P. V. Benos, Early events marking lung fibroblast transition  
726 to profibrotic state in idiopathic pulmonary fibrosis. *Respir. Res.* **24**, (2023).
- 727 27. S. Zhang, L. Zhang, L. Wang, H. Wang, J. Wu, H. Cai, C. Mo, J. Yang, Machine learning  
728 identified MDK score has prognostic value for idiopathic pulmonary fibrosis based on  
729 integrated bulk and single cell expression data. *Front. genet.* **14**, (2023).

- 730 28. T. E. King, W. Z. Bradford, S. Castro-Bernardini, E. A. Fagan, I. Glaspole, M. K.  
731 Glassberg, E. Gorina, P. M. Hopkins, D. Kardatzke, L. Lancaster, D. J. Lederer, S. D.  
732 Nathan, C. A. Pereira, S. A. Sahn, R. Sussman, J. J. Swigris, P. W. Noble, A Phase 3 Trial  
733 of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. *N. Engl. J. Med.* **370**, 2083-  
734 2092 (2014).
- 735 29. S. T. Lehtonen, A. Veijola, H. Karvonen, E. Lappi-Blanco, R. Sormunen, S. Korpela, U.  
736 Zagai, M. C. Sköld, R. Kaarteenaho, Pirfenidone and nintedanib modulate properties of  
737 fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. *Respir. Res.* **17**, (2016).
- 738 30. J. Jin, S. Togo, K. Kadoya, M. Tulafu, Y. Namba, M. Iwai, J. Watanabe, K. Nagahama, T.  
739 Okabe, M. Hidayat, Y. Kodama, H. Kitamura, T. Ogura, N. Kitamura, K. Ikeo, S. Sasaki,  
740 S. Tominaga, K. Takahashi, Pirfenidone attenuates lung fibrotic fibroblast responses to  
741 transforming growth factor- $\beta$ 1. *Respir. Res.* **20**, (2019).
- 742 31. A. Aimo, G. Spitaleri, D. Nieri, L. M. Tavanti, C. Meschi, G. Panichella, J. Lupón, F.  
743 Pistelli, L. Carrozzi, A. Bayes-Genis, M. Emdin, Pirfenidone for Idiopathic Pulmonary  
744 Fibrosis and Beyond. *Card. Fail. Rev.* **8**, (2022).
- 745 32. J.-L. Casanova, M. E. Conley, S. J. Seligman, L. Abel, L. D. Notarangelo, Guidelines for  
746 genetic studies in single patients: lessons from primary immunodeficiencies. *J. Exp. Med.*  
747 **211**, 2137-2149 (2014).
- 748 33. X. He, X. He, V. P. Dave, Y. Zhang, X. Hua, E. Nicolas, W. Xu, B. A. Roe, D. J. Kappes,  
749 The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage  
750 commitment. *Nature* **433**, 826-833 (2005).
- 751 34. X. He, K. Park, H. Wang, X. He, Y. Zhang, X. Hua, Y. Li, D. J. Kappes, CD4-CD8 Lineage  
752 Commitment Is Regulated by a Silencer Element at the ThPOK Transcription-Factor  
753 Locus. *Immunity* **28**, 346-358 (2008).
- 754 35. G. Sun, X. Liu, P. Mercado, S. R. Jenkinson, M. Kypriotou, L. Feigenbaum, P. Galéra, R.  
755 Bosselut, The zinc finger protein cKrox directs CD4 lineage differentiation during  
756 intrathymic T cell positive selection. *Nat. Immunol.* **6**, 373-381 (2005).
- 757 36. L. Wang, K. F. Wildt, E. Castro, Y. Xiong, L. Feigenbaum, L. Tessarollo, R. Bosselut, The  
758 Zinc Finger Transcription Factor *Zbtb7b* Represses CD8-Lineage Gene Expression in  
759 Peripheral CD4+ T Cells. *Immunity* **29**, 876-887 (2008).
- 760 37. L. Wang, K. F. Wildt, J. Zhu, X. Zhang, L. Feigenbaum, L. Tessarollo, W. E. Paul, B. J.  
761 Fowlkes, R. Bosselut, Distinct functions for the transcription factors GATA-3 and ThPOK  
762 during intrathymic differentiation of CD4+ T cells. *Nat. Immunol.* **9**, 1122-1130 (2008).
- 763 38. V. P. Dave, D. Allman, R. Keefe, R. R. Hardy, D. J. Kappes, HD mice: A novel mouse  
764 mutant with a specific defect in the generation of CD4+ T cells. *Proc. Natl. Acad. Sci.*  
765 *U.S.A* **95**, 8187-8192 (1998).
- 766 39. M. S. Vacchio, L. Wang, N. Bouladoux, A. C. Carpenter, Y. Xiong, L. C. Williams, E.  
767 Wohlfert, K.-D. Song, Y. Belkaid, P. E. Love, R. Bosselut, A ThPOK-LRF transcriptional  
768 node maintains the integrity and effector potential of post-thymic CD4+ T cells. *Nat.*  
769 *Immunol.* **15**, 947-956 (2014).
- 770 40. Y. C. Twu, H. S. Teh, The ThPOK transcription factor differentially affects the  
771 development and function of self-specific CD8(+) T cells and regulatory CD4(+) T cells.  
772 *Immunology* **141**, 431-445 (2014).
- 773 41. R. Setoguchi, I. Taniuchi, M. J. Bevan, ThPOK Derepression Is Required for Robust CD8  
774 T cell Responses to Viral Infection. *J. Immun.* **183**, 4467-4474 (2009).

- 775 42. K. R. Nitta, A. Jolma, Y. Yin, E. Morgunova, T. Kivioja, J. Akhtar, K. Hens, J. Toivonen,  
776 B. Deplancke, E. E. Furlong, J. Taipale, Conservation of transcription factor binding  
777 specificities across 600 million years of bilateria evolution. *Elife* **4**, (2015).
- 778 43. D. Schmidt, M. D. Wilson, C. Spyrou, G. D. Brown, J. Hadfield, D. T. Odom, ChIP-seq:  
779 Using high-throughput sequencing to discover protein–DNA interactions. *Methods* **48**,  
780 240-248 (2009).
- 781 44. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**,  
782 357-359 (2012).
- 783 45. P. Danecek, J. K. Bonfield, J. Liddle, J. Marshall, V. Ohan, M. O. Pollard, A. Whitwham,  
784 T. Keane, S. A. McCarthy, R. M. Davies, H. Li, Twelve years of SAMtools and BCFtools.  
785 *GigaScience* **10**, (2021).
- 786 46. Y. Zhang, T. Liu, C. A. Meyer, J. Eeckhoute, D. S. Johnson, B. E. Bernstein, C. Nusbaum,  
787 R. M. Myers, M. Brown, W. Li, X. S. Liu, Model-based Analysis of ChIP-Seq (MACS).  
788 *Genome Biol.* **9**, R137 (2008).
- 789 47. C. E. Grant, T. L. Bailey, W. S. Noble, FIMO: scanning for occurrences of a given motif.  
790 *Bioinformatics* **27**, 1017-1018 (2011).
- 791 48. A. R. Quinlan, I. M. Hall, BEDTools: a flexible suite of utilities for comparing genomic  
792 features. *Bioinformatics* **26**, 841-842 (2010).
- 793 49. P. D. Thomas, D. Ebert, A. Muruganujan, T. Mushayahama, L. P. Albou, H. Mi,  
794 PANTHER: Making genome-scale phylogenetics accessible to all. *Protein Sci.* **31**, 8-22  
795 (2022).
- 796 50. S. Waise, R. Parker, M. Rose-Zerilli, D. Layfield, O. Wood, J. West, C. Ottensmeier, G.  
797 Thomas, C. Hanley, An Optimized Method to Isolate Human Fibroblasts from Tissue for  
798 Ex Vivo Analysis. *BIO-PROTOCOL* **9**, (2019).
- 799

800 **Acknowledgments:**

801 We thank the patient and their family members for their participation in our study. We also  
802 acknowledge the BC Children's Hospital BioBank for providing age-matched healthy control  
803 PBMC samples. Additionally, we thank Dr. Jonathan Bramson's lab at McMaster University,  
804 Ontario, Canada, for providing the optimized lentivirus transduction protocol.

805

806 **Funding:**

807 Canadian Institutes of Health Research PJQ-173584 (SET)  
808 Genome British Columbia SIP007 (SET)  
809 Tier 1 Canada Research Chair in Pediatric Precision Health (SET)  
810 Aubrey J. Tingle Professor of Pediatric Immunology (SET)  
811 Health Professional-Investigator of the Michael Smith Foundation for Health Research (CMB)  
812 Providence Healthcare Research Institute Early Career Investigator award (CMB)  
813 Vanier Canada Graduate Scholarship (MV-S)  
814 Four Year Doctoral Fellowship (MV-S, SS)  
815



816 **Author contributions:**

817 Conceptualization: MV-S, MS, CMB, SET  
818 Wet lab experiments: MV-S, MS, PY, SS, RR, AHWY, MB  
819 Clinical data acquisition: CMB, SET, MV-S, PY, AFL, JHR, CLY, KJH, RB, MKD  
820 Methodology: MV-S, MS, LDN, TRH, RB  
821 Bioinformatic analyses: MS, MV-S, KUL, AJ, MA, PAR  
822 Visualization: MV-S, MS, LG, KUL  
823 Funding acquisition: CMB, SET  
824 Supervision: CMB, SET  
825 Writing – original draft: MV-S, MS  
826 Writing – review & editing: All authors

827 **Competing interests:** The authors declare that they have no conflicts of interest related to this  
828 manuscript.


829 **Data and materials availability:** HT-SELEX and CHIP-sequencing data is available from ENA  
830 and SRA databases under accession: PRJEB75580.





831  
832

833 **Figure 1. Trio genome sequencing revealed a *de novo* heterozygous missense variant in**  
834 ***ZBTB7B* in a pediatric patient with a multi-system disorder. (A)** A summary of patient's  
835 clinical features. **(B)** Chest x-ray showing hyperinflated lungs, coarse reticular shadowing, and  
836 interstitial septal thickening. **(C)** Chest CT (coronal view) showing ground glass opacity and  
837 subpleural honeycombing changes. **(D)** Low-power view lung wedge biopsy (H&E stain). **(E)**  
838 CD20 immunohistochemistry highlights (in brown) the B cell population of the lymphoid  
839 aggregates in the interlobular septa. **(F)** CD3 immunohistochemistry highlights (in brown) the T  
840 cell population of the lymphoid aggregates in the interlobular and alveolar septa. **(G)** Subpleural  
841 honeycomb change is evident on trichrome stain, which highlights the interstitial fibrosis in blue.  
842 **(H)** The lung architectural abnormalities are patchy (non-uniform), as demonstrated by relatively  
843 normal parenchyma in the top half of this image, and interstitial fibrosis and alveolar widening in  
844 the lower half (trichrome stain). The patchy changes can also be appreciated in the low-power  
845 photomicrographs. **(I)** Some alveoli contain aggregates of alveolar macrophages surrounding  
846 cholesterol clefts (arrowhead), as well as amorphous eosinophilic material (arrow) (H&E stain).  
847 All images have scale bars embedded in the respective panels. **(J)** Illustration of the ThPOK  
848 protein, with four C-terminal zinc fingers responsible for DNA-binding to the consensus sequence  
849 and the N-terminal protein-binding BTB/POZ domain. Location of the variant  
850 (NM\_001256455.2:c.1080A>C, p.Lys325Asn) is shown (red dot). ZF, zinc finger. **(K)** Family  
851 pedigree of the patient. Filled symbols = affected individuals; unfilled symbols = unaffected  
852 individuals. WT, wild-type. **(L)** Sanger sequencing results of all family members indicating  
853 heterozygous substitution at position 1080 found only in the proband.




854

855 **Figure 2. ThPOK<sup>K360N</sup> showed altered DNA-binding specificity.** (A) Comparative analysis of  
856 ThPOK<sup>K360N</sup> and ThPOK<sup>WT</sup> protein expression using immunoblotting in HEK293 cells. Protein  
857 was detected using anti-ThPOK and anti-Myc antibodies. β-actin was assessed as loading control.  
858 Representative blot from three independent experiments. (B-C) Luciferase reporter assay using a




859 region of *SOCS1* promoter in HEK293 cells transfected with various combinations and ratios of  
860 vectors indicated below the plot. Firefly luciferase activity was normalized to Renilla luciferase to  
861 account for transfection efficiency variations, with values further normalized to the empty vector  
862 (EV) condition, offering a relative comparison to the EV baseline. Data are presented as mean  $\pm$   
863 SEM, derived from three independent biological replicates, each comprising of the average of three  
864 technical replicates. For panel B, statistical analysis was conducted using one-way ANOVA for  
865 repeated measures, with Sidak's method applied for multiple comparisons correction. For panel C,  
866 dotted lines represent the 95% confidence intervals for the Pearson correlation coefficient. **(D)**  
867 EMSA showing *in vitro* DNA binding of ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup>. Whole cell lysates of  
868 HEK293 cells transfected with an expression vector encoding each protein were incubated with  
869 infrared fluorescent dye labeled *SOCS1* probe. Anti-ThPOK antibody generated a supershift of the  
870 DNA–protein complexes (red arrow). Representative image from three independent experiments.  
871 **(E)** Competitor EMSA assay using an unlabeled (cold) probe identical to the labelled probe  
872 sequence. **(F)** Position weight matrices (PMW) for ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup>, identified from  
873 HT-SELEX data, showing the relative frequency of nucleotide occurrence at each position within  
874 the binding site. **(G)** Relative binding affinities of ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup> to all 8-base long  
875 DNA sequences (8-mers). Each point on the plot represents a unique 8-mer, with Z-scores  
876 calculated from the number of occurrences of the 8-mer in bound DNA sequences in the third HT-  
877 SELEX cycle. The sequence of top 8-mer for each protein variant is shown, as well as marginal  
878 distributions of 8-mer Z-scores (top and right side of the scatter plot). **(H)** EMSA showing *in vitro*  
879 DNA binding of ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup> to variant probes designed using binding sequences  
880 revealed by HT-SELEX. **(I)** Schematic depicting identification of ThPOK<sup>WT</sup> and ThPOK<sup>K360N</sup>  
881 regulated genes, i.e., genes with a high-confidence binding site of the protein variant within its

882 promoter region. For each protein variant, high confidence binding sites were identified as loci  
883 with a PWM hit (using HT-SELEX derived motifs) that overlapped a peak from each ChIP-seq  
884 replicate. These loci were mapped to promoter regions 1 kb upstream to 0.5 kb downstream of a  
885 transcription start site (TSS) to identify genes that are likely regulated by each protein variant.  
886 Numbers in the Venn diagram show the total number of genes regulated by ThPOK<sup>WT</sup> and  
887 ThPOK<sup>K360N</sup>, 36 of which are shared between both.




889 **Figure 3. Patients CD4+ T cells exhibit impaired development and Th2 skewing post**  
890 **stimulation. (A)** Schematic representation of ThPOK's role in T cell lineage commitment. **(B)**  
891 Clinical flow cytometry of patient's CD3+, CD4+, and CD8+ cells over time compared to pediatric  
892 healthy control (normal) range. **(C)** Absolute eosinophil count and serum IgE levels determined  
893 by the clinical laboratory over time. **(D)** Representative flow cytometry plots illustrating the  
894 proportions of CD4+ and CD8+ T cells in the patient compared to age-matched pediatric and adult  
895 healthy controls (HCs). HC, healthy control; A-HC, adult healthy control; P-HC, pediatric healthy  
896 control. Scatter dot plots summarize results from three independent blood draws for the patient  
897 compared to three age-matched pediatric (P-HC) and four adult HCs (A-HC). **(E)** Representative  
898 flow cytometry plots showing the proportions of memory and naive CD4+ T cells in the patient,  
899 identified by CCR7 and CD45RA markers, compared to age-matched pediatric and adult HCs.  
900 Scatter dot plots summarize results from three independent blood draws for the patient compared  
901 to three age-matched pediatric and four adult HCs. **(F-G)** Representative flow cytometry plots and  
902 analysis of Th2 cytokine production (IL-4, IL-5, and IL-13) in memory CD4+ T cells post-  
903 PMA/ionomycin stimulation. Scatter dot plots display comparative results. Data are mean  $\pm$  SEM;  
904 statistical significance assessed by one-way ANOVA, with Dunnett's method applied for multiple  
905 comparisons correction.



906

907

908 **Figure 4. Patient T cells exhibit distinct clustering and gene expression profiles compared to**  
909 **healthy controls. (A)** UMAP analysis of peripheral blood mononuclear cells from the patient and  
910 two age-matched healthy controls (HCs). HC, healthy controls; PBMC, peripheral blood  
911 mononuclear cells **(B)** scRNA-seq/Ab-seq analysis reflecting the proportion of CD4<sup>+</sup> single  
912 positive, CD8<sup>+</sup> single positive, double positive (DP) and double negative (DN) T cells in the  
913 patient and two HCs. **(C)** UMAP analysis of T cell clustering reveals distinct gene signatures  
914 between patient T cells and HCs. **(D)** Volcano plot comparing the differential expression of genes  
915 between DP cells of the patient in comparison to two age-matched HCs using scRNA-seq. **(E-H)**  
916 Transcriptome and Hallmark pathway analysis of post-TCR stimulated naïve CD4<sup>+</sup> (in E and F)  
917 and CD8<sup>+</sup> T cells (in G and H) in the patient compared to two age-matched HCs. **(I)** Pathway  
918 analysis of the differentially expressed genes assessed by RNA sequencing in HC T cells  
919 transduced with empty vector (EV), wild-type (WT), and p.K360N ThPOK.



920

921 **Figure 5. Expression of ThPOK<sup>K360N</sup> impairs the suppression of profibrotic genes in primary**

922 **pulmonary fibroblasts. (A)** Expression of *COL2A1* measured by qPCR in HEK293 cells

923 transfected with various constructs: empty vector (EV), wild-type (WT) ThPOK, p.K360N variant,

924 or a combination of WT and the variant. Data are mean ± SEM; n=4 experiments; statistical

925 significance assessed by one-way ANOVA, with Dunnett's method applied for multiple

926 comparisons correction. **(B)** Experimental schema depicting the transduction of healthy control

927 primary human pulmonary fibroblasts. **(C)** PCA plot of healthy control primary human pulmonary

928 fibroblasts transduced with WT ThPOK, p.K360N variant, or EV. **(D-E)** Heatmap and Venn

929 diagram illustrating gene expression variations across all three groups in healthy control primary  
930 human pulmonary fibroblasts. Each group includes three biological replicates, with each replicate  
931 consisting of independently transduced, sorted, processed, and sequenced samples. **(F)** Sample  
932 Level Enrichment Analysis (SLEA) of transduced healthy control lung fibroblasts **(G)** Expression  
933 of profibrotic genes in transduced healthy control lung fibroblasts **(H)** Experimental schema  
934 showing patient-derived primary pulmonary fibroblasts, transduced with WT ThPOK, p.K360N  
935 variant, or EV. **(I)** Expression of profibrotic genes in transduced patient-derived primary lung  
936 fibroblasts **(J)** Expression of *ACTA2*, a known profibrotic marker, measured by qPCR to evaluate  
937 the effect of pirfenidone and nintedanib on profibrotic gene expression in TGF- $\beta$ -treated patient-  
938 derived pulmonary fibroblasts. Data are mean  $\pm$  SEM; n=6 experiments; statistical analysis was  
939 conducted using one-way ANOVA for repeated measures, with post-hoc comparisons performed  
940 using Fisher's LSD test.